Comments
Suven Life Sciences on Tuesday said it had been granted a product patent from Australia and another from Hong Kong. The patents correspond to the New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases and are valid through 2036 and 2033, respectively. The granted claims are for the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, Attention Deficient Hyperactivity Disorder, Huntington’s disease, Parkinson’s and schizophrenia. Shares of Suven Life edged down 0.49 per cent at ₹252.60 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.